ClinicalTrials.gg
CompletedNCT00751777Updated Jan 29, 2020Results posted

Traveler's Diarrhea (TD) Automated Process

A Phase 2 interventional study of heat-labile enterotoxin of E. coli (LT) and Placebo in Prevention of Travelers' Diarrhea, sponsored by Intercell USA, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-29.

Sponsored by Intercell USA, Inc. (part of Valneva) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Diarrhea with a site in United States — 15 open to participants now, 20 under way, none of them phase 3. Diarrhea · United States.

Enrollment
72nd of 223
120 · median 63
Started
2008
with 8 others
Phase 2
64 of 249
3 open now
Registered
70th of 249
by date
Lead sponsor
5 of 249
Intercell USA, Inc.

Among the 249 studies in Diarrhea with a site in United States, this one is the 72nd largest by enrollment of the 223 interventional ones that give a count, is one of 9 that started in 2008, is one of 64 in phase 2, and was the 70th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

15 of the 249 studies in Diarrhea with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Diarrhea with a site in United States, or all of them as a file.
02

Study summary

To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.

03

Conditions studied

  • Prevention of Travelers' Diarrhea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males or females, 18-64 years of age (inclusive) at the planned start of the study (first vaccination on Day 0)
  • Signed
  • Women who are not or surgically sterile must have a negative serum/urine pregnancy test at screening and within 24 hours of each vaccination with understanding (through Informed Consent process) to not become pregnant and to employ an effective form of for the duration of the study. Acceptable forms of birth control are: abstinence, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and IUD.

Exclusion criteria

Exclusion Criteria:

  • Laboratory abnormalities [as determined by the Toxicity Grading Scale (grade 1 4)] at laboratory screening
  • Abnormalities at physical examination [as determined by the Toxicity Grading Scale (grade 1-4)]
  • Known allergies to any component of the vaccine
  • Known allergies to adhesives
  • Participated in research involving product within 30 days before planned date of first vaccination or within 90 days after first vaccination
  • Donated blood or blood products such as plasma within 30 days prior to planned date of first vaccination or within 90 days after first vaccination
  • Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd
  • Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™)
  • History of diarrhea while traveling in a developing country within the last year
  • History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery, liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries not pertaining to gastrointestinal problems) or history of, or recent acute gastrointestinal illness
  • Positive serology for -1, HIV-2, , or
  • Medical history of acute or chronic skin disease at vaccination area(s)
  • Active skin allergy
  • Signs of acute skin infection, sunburn or skin abnormalities at the vaccination area(s) including fungal infections, severe acne, or active contact dermatitis, or a history of keloid formation
  • Excessively hirsute and unwilling to clip hair at the vaccination area(s)
  • Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent appropriate dermatologic monitoring of the vaccination site(s)
  • Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination
  • Women who are pregnant or breastfeeding
  • Acute illness at screening and unresolved at time of planned vaccination
  • Employee of the investigational site
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Group 1: 37.5 µg LT patch

    80 subjects will receive a two vaccination regimen with a LT patch.

    Biological: heat-labile enterotoxin of E. coli (LT)

  • Placebo comparator
    Group 2: 0 µg LT patch (placebo)

    40 subjects will receive a two vaccination regimen with a placebo patch.

    Biological: Placebo

Interventions

  • Biologicalheat-labile enterotoxin of E. coli (LT)

    Travelers' Diarrhea Vaccine System

    Also known as: TD Vaccine System

  • BiologicalPlacebo

    Travelers' Diarrhea Vaccine System

    Also known as: TD Vaccine System

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo

    Time frame: Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194

  2. Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo

    GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.

    Time frame: Day 14, Day 21, Day 28, Day 35, Day 90, Day 194

  3. Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo

    Definition of SCR: * Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline * Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline

    Time frame: Day 14, Day 21, Day 28, Day 35, Day 90, Day 194

Secondary outcomes

  1. Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch

    LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)

    Time frame: 13 months

  2. Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear

    Time frame: 1 month

  3. Evaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group

    GMT

    Time frame: 13 months

  4. Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group

    GMFR

    Time frame: 13 months

  5. Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group

    SCR

    Time frame: 13 months

07

Results

Posted Apr 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
Started8139
Completed7036
Not completed113

Outcome measures

PrimaryGeometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
Time frame:
Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Reported as:
Geometric mean · geometric mean titer
Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
geometric mean titerGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
GMT LT IgG - Day 0432.6 (349.0 to 536.2)400.5 (290.5 to 552.2)
GMT LT IgG - Day 144477.5 (3249.6 to 6169.4)490.6 (303.8 to 792.2)
GMT LT IgG - Day 219107.7 (6791.9 to 12213.0)462.1 (298.0 to 716.6)
GMT LT IgG - Day 2813411.9 (10420 to 17263.5)372.6 (255.4 to 543.4)
GMT LT IgG - Day 3515024.3 (11893 to 18979.4)383.6 (270.5 to 544.0)
GMT LT IgG - Day 906823.7 (5553.1 to 8385.1)156.2 (114.5 to 213.1)
GMT LT IgG - Day 1942489.2 (1965.5 to 3152.4)100.2 (70.7 to 142.0)
GMT LT IgA - Day 049.4 (37.4 to 65.1)58.9 (38.9 to 89.1)
GMT LT IgA - Day 14395.6 (289.9 to 539.8)59.1 (37.2 to 94.1)
GMT LT IgA - Day 21619.2 (466.2 to 822.4)60.9 (39.8 to 93.0)
GMT LT IgA - Day 28780.0 (603.8 to 1007.7)53.9 (36.8 to 79.1)
GMT LT IgA - Day 35681.2 (526.1 to 882.0)52.5 (35.7 to 77.3)
GMT LT IgA - Day 90348.1 (280.3 to 432.4)40.5 (29.2 to 56.1)
GMT LT IgA - Day 194177.0 (145.3 to 215.5)32.6 (24.3 to 43.6)
PrimaryGeometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo

GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.

Time frame:
Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Reported as:
Number · ratio
Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
ratioGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
GMFR LT IgG - Day 1410.4 (7.4 to 14.5)1.2 (0.7 to 2.0)
GMFR LT IgG - Day 2121.1 (15.2 to 29.2)1.2 (0.7 to 1.9)
GMFR LT IgG - Day 2831.0 (23.5 to 41.0)0.9 (0.6 to 1.4)
GMFR LT IgG - Day 3534.7 (26.6 to 45.4)1.0 (0.6 to 1.4)
GMFR LT IgG - Day 9016.0 (12.4 to 20.8)0.4 (0.3 to 0.6)
GMFR LT IgG - Day 1945.7 (4.3 to 7.5)0.2 (0.2 to 0.4)
GMFR LT IgA - Day 148.0 (5.8 to 11.0)1.0 (0.6 to 1.6)
GMFR LT IgA - Day 2112.5 (9.3 to 16.8)1.0 (0.7 to 1.6)
GMFR LT IgA - Day 2815.8 (12.1 to 20.7)0.9 (0.6 to 1.4)
GMFR LT IgA - Day 3513.8 (10.6 to 17.9)0.9 (0.6 to 1.3)
GMFR LT IgA - Day 907.1 (5.5 to 9.2)0.6 (0.4 to 1.0)
GMFR LT IgA - Day 1943.4 (2.6 to 4.6)0.5 (0.3 to 0.8)
PrimarySeroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo

Definition of SCR: * Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline * Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline

Time frame:
Day 14, Day 21, Day 28, Day 35, Day 90, Day 194
Reported as:
Number · percentage of participants
Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo
percentage of participantsGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
SCR LT IgG - Day 1477.6 (66.6 to 86.4)8.8 (1.9 to 23.7)
SCR LT IgG - Day 2189.5 (80.3 to 95.3)8.8 (1.9 to 23.7)
SCR LT IgG - Day 2897.4 (90.8 to 99.7)2.9 (0.1 to 15.3)
SCR LT IgG - Day 3597.4 (90.8 to 99.7)5.9 (0.7 to 19.7)
SCR LT IgG - Day 9098.7 (92.8 to 100)9.1 (1.9 to 24.3)
SCR LT IgG - Day 19483.3 (72.7 to 91.1)0 (0 to 10.6)
SCR LT IgA - Day 1457.9 (46.0 to 69.1)0.0 (0.0 to 10.3)
SCR LT IgA - Day 2171.1 (59.5 to 80.9)0.0 (0.0 to 10.3)
SCR LT IgA - Day 2882.9 (72.5 to 90.6)0.0 (0.0 to 10.3)
SCR LT IgA - Day 3581.6 (71.0 to 89.5)2.9 (0.1 to 15.3)
SCR LT IgA - Day 9068.0 (56.2 to 78.3)3.0 (0.1 to 15.8)
SCR LT IgA - Day 19450.0 (38.0 to 62.0)0.0 (0.0 to 10.6)
SecondaryEvaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch

LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)

Time frame:
13 months
Reported as:
Count of participants · Participants
Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch
ParticipantsGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
AEs : All AEs - vaccination 17526
AEs : All AEs - vaccination 27624
AEs : Local AEs - vaccination 17319
AEs : Systemic AEs - vaccination 14318
AEs : Local AEs - vaccination 27313
AEs : Systemic AEs - vaccination 24418
Severe AEs : All AEs - vaccination 122
Severe AEs : All AEs - vaccination 220
Severe AEs : Local AEs - vaccination 100
Severe AEs : Systemic AEs - vaccination 122
Severe AEs : Local AEs - vaccination 200
Severe AEs : Systemic AEs - vaccination 220
AEs requiring Treatment : All AEs - vaccination 1246
AEs requiring Treatment : All AEs - vaccination 23310
AEs requiring Treatment : Local AEs - vacc. 1100
AEs requiring Treatment : Systemic AEs - vacc. 1166
AEs requiring Treatment : Local AEs - vacc. 240
AEs requiring Treatment : Systemic AEs - vacc. 23110
related AEs : All AEs - vaccination 17420
related AEs : All AEs - vaccination 27413
related AEs : Local AEs - vaccination 17319
related AEs : Systemic AEs - vaccination 1175
related AEs : Local AEs - vaccination 27313
related AEs : Systemic AEs - vaccination 263
Serious AEs : All AEs - vaccination 101
Serious AEs : All AEs - vaccination 211
Serious AEs : Local AEs - vaccination 100
Serious AEs : Systemic AEs - vaccination 101
Serious AEs : Local AEs - vaccination 200
Serious AEs : Systemic AEs - vaccination 211
SecondaryEvaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear
Time frame:
1 month
Reported as:
Mean · nanograms (ng)
Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear
nanograms (ng)Group 1: 37.5 µg LT Patch
Residual LT in the Patch (ng LT)15893 ± 6980
Residual LT in the Swab (ng LT)7231 ± 2939
Estimate of LT Delivered (ng LT)14376 ± 7609
SecondaryEvaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group

GMT

Time frame:
13 months
Reported as:
Geometric mean · GMT
Evaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group
GMTGroup 1: 37.5 µg LT Patch
GMT LT IgG - Day 3801653.7 (1377.9 to 1984.8)
GMT LT IgA - Day 380122.3 (98.3 to 152.1)
SecondaryEvaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group

GMFR

Time frame:
13 months
Reported as:
Geometric mean · ratio
Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group
ratioGroup 1: 37.5 µg LT Patch
GMFR LT IgG - Day 3803.8 (3.0 to 4.9)
GMFR LT IgA - Day 3802.4 (1.8 to 3.3)
SecondaryEvaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group

SCR

Time frame:
13 months
Reported as:
Number · percentage of participants
Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group
percentage of participantsGroup 1: 37.5 µg LT Patch
SCR LT IgG - Day 38067.1 (54.9 to 77.9)
SCR LT IgA - Day 38038.6 (27.2 to 51.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: 37.5 µg LT Patch—1/81 (1.2%)79/81 (97.5%)
Group 2: 0 µg LT Patch (Placebo)—2/39 (5.1%)32/39 (82.1%)
Most frequent serious events
Most frequent serious events
EventGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
Haemorrhoidal haemorrhageGastrointestinal disorders0/811/39
GastroenteritisInfections and infestations0/811/39
Non-cardiac chest painGeneral disorders1/810/39
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGroup 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)
Application site rashInjury, poisoning and procedural complications77/815/39
Application site erythemaInjury, poisoning and procedural complications72/8114/39
Application site pruritusInjury, poisoning and procedural complications72/818/39
Application site discolourationInjury, poisoning and procedural complications62/815/39
Application site painInjury, poisoning and procedural complications22/813/39
DiarrhoeaGastrointestinal disorders11/814/39
Application site oedemaInjury, poisoning and procedural complications11/810/39
Upper respiratory tract infectionInfections and infestations7/814/39
Blood glucose increasedInvestigations6/813/39
Protein urine presentInvestigations4/813/39

Baseline characteristics

Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology

Age, Continuous
Age, Continuous(years)Group 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)Total
Mean34.1 ± 10.235.3 ± 13.034.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: 37.5 µg LT PatchGroup 2: 0 µg LT Patch (Placebo)Total
Female462672
Male351348
08

Study locations

3 sites
  • Solano Clinical Research
    Vallejo, California 94589, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2008
First posted
Sep 12, 2008
Start
Sep 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Apr 21, 2014
Last update
Jan 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00751777
Responsible party
Sponsor
First posted
Sep 12, 2008
Start date
Sep 2008
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Apr 21, 2014
Last update
Jan 29, 2020

Study contacts

Eric Sheldon, MD
principal investigator · Miami Research Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion